Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infe… Read more
Market Cap & Net Worth: Cisen Pharmaceutical Co Ltd (603367)
Cisen Pharmaceutical Co Ltd (SHG:603367) has a market capitalization of $1.05 Billion (CN¥7.74 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #10526 globally and #2359 in its home market, demonstrating a 3.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cisen Pharmaceutical Co Ltd's stock price CN¥17.09 by its total outstanding shares 452754129 (452.75 Million).
Cisen Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Cisen Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $1.10 Billion to $1.05 Billion (1.48% CAGR).
Cisen Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cisen Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Cisen Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.67x
Cisen Pharmaceutical Co Ltd's market cap is 1.67 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.10 Billion | $2.96 Billion | $367.22 Million | 0.37x | 2.99x |
| 2018 | $847.05 Million | $3.81 Billion | $503.54 Million | 0.22x | 1.68x |
| 2019 | $939.20 Million | $4.11 Billion | $514.58 Million | 0.23x | 1.83x |
| 2020 | $801.65 Million | $3.67 Billion | $438.78 Million | 0.22x | 1.83x |
| 2021 | $785.50 Million | $3.78 Billion | $334.15 Million | 0.21x | 2.35x |
| 2022 | $760.16 Million | $4.07 Billion | $349.96 Million | 0.19x | 2.17x |
| 2023 | $903.38 Million | $4.46 Billion | $521.34 Million | 0.20x | 1.73x |
| 2024 | $847.84 Million | $3.98 Billion | $508.91 Million | 0.21x | 1.67x |
Competitor Companies of 603367 by Market Capitalization
Companies near Cisen Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Cisen Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Cisen Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Cisen Pharmaceutical Co Ltd's market cap moved from $1.10 Billion to $ 1.05 Billion, with a yearly change of 1.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.05 Billion | -1.33% |
| 2025 | CN¥1.07 Billion | +26.06% |
| 2024 | CN¥847.84 Million | -6.15% |
| 2023 | CN¥903.38 Million | +18.84% |
| 2022 | CN¥760.16 Million | -3.23% |
| 2021 | CN¥785.50 Million | -2.01% |
| 2020 | CN¥801.65 Million | -14.65% |
| 2019 | CN¥939.20 Million | +10.88% |
| 2018 | CN¥847.05 Million | -22.98% |
| 2017 | CN¥1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Cisen Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.05 Billion USD |
| MoneyControl | $1.05 Billion USD |
| MarketWatch | $1.05 Billion USD |
| marketcap.company | $1.05 Billion USD |
| Reuters | $1.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.